| Study Period | 2021 - 2030 |
| Market Size (2025) | USD 29.16 Billion |
| Market Size (2030) | USD 43.85 Billion |
| CAGR (2025 - 2030) | 8.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Abortion Drugs Market Analysis
The Abortion Drugs Market size is estimated at USD 29.16 billion in 2025, and is expected to reach USD 43.85 billion by 2030, at a CAGR of 8.5% during the forecast period (2025-2030).
The abortion drugs market is anticipated to experience significant growth in the coming years. This growth is driven by factors such as the increasing rate of unintended pregnancies, greater acceptance and awareness of abortion drugs, and a rising number of abortion cases. Additionally, the growing number of prescriptions for abortion drugs and their improved commercial availability are expected to boost their adoption further, thereby driving market growth.
The growing proportion of unintended pregnancies is likely to fuel the demand for abortion drugs as they prevent and block the action of the hormone progesterone that supports the pregnancy. For instance, in June 2024, a study published in Reproductive Health reported a 30.7% prevalence of unintended pregnancies among women in Tabriz, Iran. The findings indicated that these unintended pregnancies had a detrimental impact on women's overall pregnancy experiences, contributing to reduced satisfaction levels and elevated stress.
The findings underscored the urgent need for tailored interventions, such as abortion drugs, to address these issues and improve reproductive health policies in the region. Hence, the growing incidence of unintended pregnancies is likely to accelerate the adoption of abortion drugs, thereby supporting market growth.
Also, the notable usage of medications for abortion is another factor projected to propel the demand for innovative abortion drugs to avoid unwanted pregnancies. For instance, a March 2024 research from the Monthly Abortion Provision Study conducted by the New Guttmacher Institute demonstrated that around 63% of abortions, or 642,700 abortions, in the United States were medication abortions, and this trend has increased significantly from previous years. This growing use of medications for abortions is poised to push demand for new drugs, thereby opening new growth avenues for the market.
Furthermore, notable acceptance and use of abortion drugs by patients amid their proven effectiveness and efficacy have further contributed to the active medication demands. For instance, a study published in Obstetrics & Gynecology in March 2023 showed significant acceptability and efficacy of medical abortion when misoprostol is administered at home up to 70 days of gestation.
In addition, the study further concluded that these implementations contributed positively to treatment efficacy, thereby enhancing patient safety and satisfaction. Hence, such promising acceptance of abortion drugs is projected to accelerate demand for innovative therapeutics, thereby supporting industry growth.
Therefore, the above-mentioned factors, including the rising incidence of unwanted pregnancies, the growing uptake of medications for abortion, and enhanced efficacy associated with abortion drugs, are projected to support the abortion drug market.
Abortion Drugs Market Trends
Mifepristone Drug Type Segment is Expected to Dominate the Abortion Drugs Market during the Forecast Period
The mifepristone drug type segment is expected to hold a significant market share in the abortion drugs market owing to factors such as growing acceptance of non-surgical abortion methods, increased awareness of reproductive rights, and expanding access to healthcare services. Moreover, the ongoing research and development efforts aimed at improving formulations and expanding the indications for Mifepristone further solidify its position within the abortion drugs market.
Mifepristone, often referred to as the "abortion pill," functions as a progesterone receptor antagonist, effectively blocking the hormone progesterone, which is essential for maintaining pregnancy. This mechanism leads to the detachment of the uterine lining and initiates the process of abortion. For instance, an article published in the African Journal of Reproductive Health in March 2024 demonstrated mifepristone's ability to inhibit progesterone and its role in abortion. Therefore, this ability of mifepristone to inhibit progesterone release is expected to facilitate its adoption as an effective abortion drug.
Moreover, the increasing research and development efforts by the public as well as private organizations to demonstrate the combination of mifepristone therapies in abortion are likely to bolster its adoption to prevent unwanted pregnancy, thereby supporting segment growth. For instance, according to November 2024 data from the Clinical Trials. Gov, KK Women's and Children's Hospital initiated a study in November 2022 to evaluate the combination effects of mifepristone with letrozole for the pretreatment of medical termination of pregnancy, and the study showed promising outcomes during the investigation. Such promising results exhibited by combination therapies are likely to bolster the augment of mifepristone combination, opening new business avenues.
Furthermore, the convenience associated with mifepristone therapy and enhanced patient compliance are further expected to propel its adoption rates. For instance, an article published in BMJ Sexual & Reproductive Health in October 2024 demonstrated that administering mifepristone at home was as effective and safe as in-clinic intake. It underscored high patient satisfaction and compliance rates among women who opted for home use. The findings implied a significant opportunity for policy adjustments to enhance access to medical abortion services and align regulations with evidence-based practices. Such convenience factors contribute to the positive patient preference for mifepristone therapy, thereby supporting segment growth.
Additionally, various efforts undertaken by companies and distributors to foster commercial availability of mifepristone are likely to augment industry growth. For instance, in March 2024, Walgreens and CVS Pharmacy started selling prescription mifepristone in the United States. This initiative was taken after the United States Food and Drug Administration decided to allow distributors to sell the pills in the United States. Such efforts are projected to expand the commercial availability of this drug in the country.
Consequently, the above-mentioned factors are projected to foster segment expansion over the coming years.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Exhibit Lucrative Market Growth in the Abortion Drugs Market
North America is projected to witness lucrative growth opportunities over the forecast period owing to factors such as growing incidences of unwanted pregnancies and rising demand for innovative abortion drugs. In addition, increasing investigational studies to develop promising candidates for safe abortion and growing research spending to improve women’s health in the United States are further anticipated to bolster regional market growth.
The growing number of unwanted and unplanned pregnancies across North America has propelled the demand for effective abortion drugs in the region. For instance, according to October 2024 data from the Society of Obstetricians and Gynecologists of Canada, around 50% of pregnancies in Canada are unplanned and are common for women of all ages. Hence, such unplanned pregnancies are likely to propel market growth forward.
In addition, a significant number of clinical trials investigating potential candidates for abortion is further likely to propel the regional market forward. For instance, according to November 2024 data from clinical trials. Gov, there were 28 active studies for abortion in the United States. Hence, such a notable number of clinical trials for abortion in the United States are poised to offer growth momentum for the market.
Also, supportive government legislation and growing funding for women’s health research are likely to expand the development of advanced abortion medicines. For instance, according to 2024 data from the National Institutes of Health, the research funding for women’s health rose from 4,587 million in 2023 to 5,049 in 2024 in the United States. Such research fundings are projected to fuel research in the women’s health sector, including the development of promising abortion as well as contraception agents.
Therefore, the above-mentioned factors, including the rising incidence of unwanted pregnancies in the region and growing R&D activities to develop promising abortion candidates, are likely to enhance regional market growth.
Get Analysis on Important Geographic Markets
Download PDF
Abortion Drugs Industry Overview
The abortion drugs market is competitive in nature due to the presence of several companies globally, the market studied is fragmented. The studied market consists of several international companies, which hold most of the market shares and are well known, including Cipla, Mankind Pharma, GenBioPro, Corcept Therapeutics Incorporated., Pfizer Inc, EVER Pharma, Dr. Reddy’s Laboratories Ltd among others.
Abortion Drugs Market Leaders
-
Pfizer Inc
-
Dr. Reddy’s Laboratories Ltd
-
Corcept Therapeutics Incorporated.
-
GenBioPro
-
EVER Pharma
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Abortion Drugs Market News
- May 2024: Pfizer Hospital launched Carboprost Tromethamine Injection, USP 250 mcg/mL Single Dose Vial, to its portfolio in the United States. Carboprost is one of the popular drugs to cause abortion.
- July 2023: Endo International plc and Premier, Inc. announced that Endo's Par Sterile Products division had agreed to supply Pitocin (oxytocin injection, USP) vials through Premier's ProvideGx and PremierProRx programs. Pitocin is used to induce labor in pregnant women.
Abortion Drugs Industry Segmentation
Abortion drugs, commonly referred to as medical abortion medications, are pharmaceutical agents used to terminate pregnancies through non-surgical means. These drugs, primarily mifepristone and misoprostol, offer a safe and effective alternative for women seeking to end a pregnancy within the early gestational period.
The abortion drugs market is segmented by drug type, distribution channel, and geography. By drug type the market is segmented into, mifepristone, misoprostol, pitocin, hemabate, carboprost, and others. By distribution channel the market is segmented into, hospital pharmacies, retail pharmacies and online pharmacies. The report also covers the market sizes and forecasts for the abortion drugs market in major countries across different regions. For each segment, the market size is provided in terms of value (USD).
| By Drug Type | Mifepristone | ||
| Misoprostol | |||
| Pitocin | |||
| Hemabate | |||
| carboprost | |||
| Others | |||
| By Distribution Channel | Hospital Pharmacies | ||
| Retail Pharmacies | |||
| Online Pharmacies | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Abortion Drugs Market Research FAQs
How big is the Abortion Drugs Market?
The Abortion Drugs Market size is expected to reach USD 29.16 billion in 2025 and grow at a CAGR of 8.5% to reach USD 43.85 billion by 2030.
What is the current Abortion Drugs Market size?
In 2025, the Abortion Drugs Market size is expected to reach USD 29.16 billion.
Who are the key players in Abortion Drugs Market?
Pfizer Inc, Dr. Reddy’s Laboratories Ltd, Corcept Therapeutics Incorporated., GenBioPro and EVER Pharma are the major companies operating in the Abortion Drugs Market.
Which is the fastest growing region in Abortion Drugs Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Abortion Drugs Market?
In 2025, the North America accounts for the largest market share in Abortion Drugs Market.
What years does this Abortion Drugs Market cover, and what was the market size in 2024?
In 2024, the Abortion Drugs Market size was estimated at USD 26.68 billion. The report covers the Abortion Drugs Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the Abortion Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Abortion Drugs Industry Report
Statistics for the 2025 Abortion Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Abortion Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
